|
|
Article: Conor to evaluate Novartis drugs for use in vascular DES devices.
- Article from:
- Medical Device Daily
- Article date:
- March 17, 2005
CopyrightCOPYRIGHT 2005 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Conor to evaluate Novartis drugs for use in vascular DES devices
By HOLLAND JOHNSON
Medical Device Daily Associate Managing Editor
In a move that, at least in part, could be attributed to a pending lawsuit with Angiotech Pharmaceuticals (Vancouver, British Columbia) over rights to the use of that companys paclitaxel compound on a drug-eluting stent (DES), Conor Medsystems (Menlo Park, California) reported that it has signed an agreement with Novartis Pharma (Basel, Switzerland) granting Conor the right to evaluate three Novartis pharmaceutical compounds for the potential development of a new DES product.
Conor will evaluate the ...